Article Submission
Manuscript Submission Deadline:
20 Esfand 1404 (20 March 2026)
Scope of the Congress
The International Cancer Genomics Congress 2026 (CGC2026) provides a focused international platform for the presentation and discussion of high-quality research in molecular biology and molecular genetics of cancer, with an integrated emphasis on transcriptomics, genomics, and multi-omics approaches, as well as human and clinical cancer genetics. The congress is designed to promote scientifically rigorous, data-driven, and clinically relevant research that advances the understanding of cancer initiation, progression, diagnosis, prognosis, and therapeutic strategies.
CGC2026 accepts English-language submissions only and prioritizes original contributions that address cancer through molecular, genetic, transcriptomic, and computational perspectives, with clear biological or clinical relevance. Studies combining experimental molecular biology with advanced data analysis and clinical interpretation are particularly encouraged.
Submissions aligned with the following areas are welcomed; however, submissions are not limited to these areas.
- Molecular biology and molecular genetics of cancer, including gene regulation, DNA damage and repair, chromatin biology, and oncogenic transformation
- Transcriptomics, genomics, and multi-omics in cancer, including bulk and single-cell transcriptomics, epigenomics, proteomics, metabolomics, and spatial omics
- Bioinformatics and computational analysis of omics data, including multi-omics integration, systems biology, and network-based approaches
- Machine learning and artificial intelligence in cancer research, including biomarker discovery, patient stratification, outcome prediction, and precision oncology
- Human and clinical genetics of cancer, including inherited cancer syndromes, somatic variation, molecular diagnostics, and genotype–phenotype correlations
- Non-coding RNAs and gene-regulatory networks in cancer biology
- Oncogenic signaling pathways, tumor microenvironment, and therapeutic targets
- Translational cancer research, molecular diagnostics, and clinically actionable biomarkers
- Innovative genomic and molecular technologies applied to cancer research.
Accepted Article Types
CGC2026 accepts submissions exclusively in the following categories:
- Original Research Articles
Experimental, translational, computational, or molecular studies presenting novel data and validated findings.
- Case Reports
Clinically, genetically, or molecularly informative cases with clear diagnostic or biological significance.
- Bioinformatics Studies
Computational, transcriptomic, genomic, multi-omics, machine-learning, or AI-driven analyses addressing cancer-related questions.
- Meta-Analyses
Quantitative meta-analyses based on predefined inclusion criteria, appropriate statistical methodology, and reproducible analytical workflows.
- Review articles
Narrative reviews and unsolicited systematic reviews are not accepted as regular submissions. CGC2026 will organize a Review Article Workshop by Cancer Genomics Academy.
NOTE: Only review articles developed within this workshop will be eligible for acceptance, in the following framework:
- All review articles must be developed within the workshop structure;
- Topics will be pre-assigned by the Scientific Committee.
- This structure results in unique, non-overlapping review article subjects (15 × 10).
Topics are defined by the combination of:
15 distinct cancer types:
- Breast Cancer
- Lung Cancer
- Glioblastoma Multiforme
- Leukemia
- Gastric Cancer
- Lymphoma
- Prostate Cancer
- Colorectal Cancer
- Osteosarcoma
- Ovarian Cancer
- Cervical Cancer
- Pancreatic Cancer
- Hepatocellular Carcinoma
- Esophageal Cancer
- Bladder Cancer
10 predefined thematic domains:
Multi-Omics Integration in Cancer Biology
Transcriptomics, proteomics, metabolomics, epigenomics, and single-cell approaches to uncover cancer mechanisms.
- Non-Coding RNAs and Regulatory Networks
lncRNAs, miRNAs, circRNAs, piRNAs, and their roles in tumorigenesis, metastasis, and therapy response.
- Immunotherapy and CAR-T Cell Therapy
Checkpoint inhibitors, adoptive cell therapies, tumor-infiltrating lymphocytes, and emerging immune modulators.
- Oncogenic Signaling Pathways and Therapeutic Targets
PI3K/AKT/mTOR, MAPK, Wnt/β-catenin, JAK/STAT, and other clinically actionable pathways.
- Cancer Metabolism and Metabolic Reprogramming
Warburg effect, mitochondrial dynamics, lipid metabolism, and metabolic vulnerabilities in tumors.
- Cancer Epigenetics and Chromatin Modifiers
DNA methylation, histone modifications, chromatin remodeling, and epigenetic therapy.
- Targeted Therapy and Precision Oncology
Small molecules, kinase inhibitors, PARP inhibitors, and strategies for patient stratification.
- Biomarkers in Cancer
ctDNA, cfRNA, exosomes, circulating tumor cells, protein markers, and other molecular indicators for diagnosis, prognosis, and treatment monitoring.
- Emerging Technologies and General Innovations in Cancer Research
Synthetic biology, oncolytic viruses, RNA therapeutics, nanotechnology, and other cutting-edge approaches not fully captured by the above domains.
The 3rd International Congress of Cancer Genomics (CGC2026) will be held in Isfahan – Tehran on 2026.
Useful Links
Contact Us
- Sat - Thu | 9:00 - 15:00
- +98-21-82884052
- info@icgcs.com
- Tarbiat Modares University, Nasr Bridge, Jalal Al-Ahmad Highway, Tehran, Iran
Enamad
Copyright © 2026 ICGCS